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A B S T R A C T
Genetic studies are identifying an increasing number of monogenic causes of Common Variable
Immunodeﬁciency (CVID). Pathogenic variants in the C-terminus of NFKB2 have been identiﬁed in the subset of
CVID patients whose immunodeﬁciency is associated with ectodermal dysplasia and central adrenal in-
suﬃciency. We describe 2 unrelated CVID pedigrees with 4 cases of pathogenic stop gain variants
(c.1903C > T) in the ankyrin repeat domain (ARD) of NF-κB2, leading to a premature truncation of the protein
at p.Arg635Term (R635X). By immunophenotyping and functional ex vivo B- and T-cell experiments we char-
acterized the variant by reduced class-switched memory B-cell counts and immature plasmablasts, unable to
produce IgG and IgA. Features of a poor proliferative T-cell response and reduced expansion of CD4+CXCR5+ T
cells was only observed in the two clinically aﬀected index cases without any clear clinical correlate. In con-
clusion, pathogenic stop variants in the ARD of NFKB2 can cause ‘infection-only’ CVID with an abnormal B-cell
phenotype and a variable clinical penetrance.
1. Introduction
Common variable immunodeﬁciency (CVID [MIM 607594]) is a
heterogeneous disorder characterized by sinopulmonary infections,
hypogammaglobulinemia and poor vaccine responses with a prevalence
of 1:25,000–1:50,000 [1], frequently complicated by autoimmunity,
lymphoproliferation and granulomatous disease [2]. Although initially
characterized as late-onset with a complex genetic etiology, an in-
creasing number of monogenic gene defects have been found leading to
CVID [3]. Dominant-negative heterozygous NFKB2 mutations have
been reported that result from variants in the C-terminus of the protein
causing immunodeﬁciency with characteristic features that include
ectodermal dysplasia and adrenal insuﬃciency [4–11].
Recently, Kuehn et al. described a novel case-series of patients with
more proximal NFKB2 mutations leading to an altered phenotype,
without endocrine or ectodermal manifestations [12]. This series in-
cluded 3 cases with a stop-variant c.1903C > T, p.Arg635Term
(R635X), in the ankyrin repeat domain (ARD), which lead to a gain-of-
function (GOF) disease mechanism and presented with the clinical
phenotype of combined immunodeﬁciency (CID) with defective B- and
T-cell function.
In most NFKB2-defective patients, the immunophenotypic and
functional data are not described in detail. Here we describe the clinical
and cellular phenotype of an additional 4 individuals of 2 unrelated
families with the R635X mutation, identiﬁed by Whole Genome
Sequencing (WGS) as part of the NIHR BioResource – Rare Diseases
study.
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2. Material and methods
2.1. Patient samples
All participants provided written informed consent and the study
was approved by the East of England Cambridge South national in-
stitutional review board (13/EE/0325) and the Medical Ethics
Committee of the Academic Medical Center (NL40331.078.12) in ac-
cordance with the Declaration of Helsinki.
2.2. Genetic analysis
WGS and sequence data analysis were performed as described pre-
viously [13]. Pathogenic NFKB2 variants were identiﬁed by screening
all genes previously associated with PID [14]. No other potential ge-
netic causes of CVID were identiﬁed in the two pedigrees described
here. Variants were conﬁrmed by Sanger sequencing using standard
protocols.
2.3. Immunophenotyping
Peripheral blood mononuclear cells (PBMCs) were isolated by
standard density gradient centrifugation techniques using Lymphoprep
(Nycomed, Oslo, Norway). PBMCs were resuspended in PBS, containing
0.5% (w/v) BSA and 0.01% sodium azide and incubated with saturating
concentrations of ﬂuorescently labeled conjugated monoclonal anti-
bodies. Analysis of cells was performed using a FACSCanto-II ﬂowcyt-
ometer and FlowJo software. Patient samples were analyzed simulta-
neously with PBMCs from healthy controls. The following directly
conjugated monoclonal antibodies were used: CD3 APC-R700, CD4 PE-
Cy7, CD8 PerCP-Cy5.5, CD19 APC-R700, CD20 PerCP-Cy5.5, CD21
FITC, CD27 APC, CD38 PE-Cy7, CXCR5 Alexa Fluor 488 and IgD PE
from BD (San Jose, USA), CD3 Alexa Fluor 700, CD19 Alexa Fluor 700
and CD27 APC-eFluor 780 from eBioscience (San Diego, USA), CD27
FITC from Sanquin (Amsterdam, the Netherlands), CD45RA (2H4-RD1)
PE from Beckman Coulter (Brea, USA), IgM FITC and IgG FITC from
Dako (Glostrup, Denmark), IgA FITC from Miltenyi Biotec (Bergisch
Gladbach, Germany).
2.4. B- and T-cell functional assay
To analyze the ex vivo activation of T and B cells as described pre-
viously [13,15], PBMCs were resuspended in PBS at a concentration of
5–10×106 cells/ml and labeled with 0.5 μM CFSE (Molecular Probes)
in PBS for 10min at 37 °C under constant agitation. Cells were washed
and subsequently resuspended in Iscove's Modiﬁed Dulbecco's medium
(IMDM) supplemented with 10% fetal calf serum (BioWhittaker), an-
tibiotics, and 3.57× 10−4%(v/v) β-mercaptoethanol (Merck). Labeled
PBMCs containing a ﬁxed number of 2× 104 B cells per well, were
plated in a ﬂat-bottom 96-well plate for 6 days at 37 °C and stimulated
with saturating amounts of anti-IgM mAb (clone MH15; Sanquin), anti-
CD40 mAb (clone 14G7; Sanquin) and 20 ng/ml IL-21 (Invitrogen), or
1 μg/ml CpG oligodeoxynucleotide 2006 (Invivogen) and 100 U/ml IL-2
(R&D Systems), or soluble anti-CD3 (clone 1xE), immobilized anti-CD3
(clone 16A9T), anti-CD2 (combination of clone 6G4, 4B2H4 and Hik27)
alone or in combination with anti-CD28 (clone 15E8), or IL-15 (R&D
Systems). Proliferation of B and T cells was assessed by measuring CFSE
dilution in combination with the same mAbs used for im-
munophenotyping and analyzed using a FACSCanto-II ﬂowcytometer
and FlowJo software.
Fig. 1. Reduced class-switched memory B cells in two families of NFKB2 R635X cases. (A) Pedigrees of two NFKB2 R635X families, symbol legend included. Proband/
index cases indicated with P. (B) Percentages non-switched and switched memory B cells within CD19+CD20+ B cells. HD: healthy donor, open dots are day controls
within this study, NFKB1+/−: pathologic heterozygous NFKB1 cases published previously by our group [13], NFKB2+/−: NFKB2 R635X cases within this study. (C)
Flow cytometry plots of CD27+IgG+ (left), IgG+IgD+ (middle), CD27+IgA+ (right) within CD19+CD20+ B cells.
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2.5. ELISA
The secretion of immunoglobulins by mature B cells was assessed by
testing supernatants for secreted IgM, IgG and IgA with an in-house
ELISA using polyclonal rabbit anti-human IgM, IgG and IgA reagents
and a serum protein calibrator all from Dako (Glostrup, Denmark).
3. Results and discussion
In a cohort of 447 unrelated CVID patients sequenced as part of the
NIHR BioResource - Rare Diseases study, we identiﬁed two index cases
who had the recently reported NFKB2 GOF mutation c.1903C > T,
leading to a premature stop p.Arg635Term (R635X) [12]. The index
case in Family A was sequenced as part of an apparently autosomal-
dominant pedigree with whole genome sequence data available for
both parents and four children (Fig. 1A). The R635X variant was found
to be inherited, as expected, from the index case (A:I-2) by her clinically
aﬀected son (A:II-4); unexpectedly, however, it was also inherited by
one of the three clinically unaﬀected children (A:II-1). No other pa-
thogenic variants co-segregating with the disease phenotype were
identiﬁed.
The Family A index case (A:I-2) experienced frequent infections,
mainly sinopulmonary and gastrointestinal (Giardia lamblia) infections
with concomitant nodular lymphoid hyperplasia. Serum im-
munoglobulins (IgG, IgM and IgA) were low at presentation. Treatment
with intravenous immunoglobulin (IVIG) was successfully initiated. Of
the two children who inherited the R635X variant, only one son was
diagnosed with CVID (A:II-4) because of frequent sinopulmonary in-
fections and hypogammaglobulinemia, whereas the eldest son re-
mained clinically unaﬀected at the time of the study (A:II-1). Both ge-
netically aﬀected sons were deﬁcient for circulating IgA in plasma like
the mother, although also the genetically unaﬀected son (A:II-2) was
found to be IgA-deﬁcient.
In Family B, the index patient (B:II-1) suﬀered from recurrent si-
nopulmonary infections (including pneumonia), with low vaccine re-
sponses and hypogammaglobulinemia. All three major serum im-
munoglobulin isotypes (IgG, IgM and IgA) were low at presentation,
whereas the unaﬀected sibling showed normal levels (data not shown).
No warts or other frequent viral infections nor any autoimmunity was
present in B:II-1. Since IVIG treatment was initiated the patient is
clinically stable. Her clinically unaﬀected sister was conﬁrmed not to
carry the R635X variant. EBV viral loads were undetectable in all de-
scribed cases (A:I-2, A:II-4, A:II-1 and B:II-1). To summarize, we found
that in these patients the R635X variant leads to CVID, but without any
of the previously described clinical signs of T-cell dysfunction, auto-
immune disease or adrenal insuﬃciency in these two unrelated fa-
milies.
Upon phenotyping of the B- and T-cell compartment in members of
both pedigrees, B-cell lymphopenia (0.08 and 0.02× 109/L) was seen
in both NFKB2-deﬁcient index cases. Similar to NFKB1 loss-of-function
mutations, a reduction in class-switched memory B cells was observed
(Fig. 1B). Both index cases showed skewed B-cell diﬀerentiation with an
atypical distribution of IgG+ memory B cells and a complete absence of
memory IgA+ B cells (Fig. 1C). In contrast to NFKB1 loss-of-function B
cells [13], there was no increase in CD21low B cells (< 10% [16], data
not shown), irrespective of clinical phenotype.
There was normal B-cell proliferation upon T cell-independent and
-dependent activation and plasmablast formation also seemed un-
aﬀected in all four NFKB2 R635X carriers (Fig. 2A, representative
plots). However, whilst plasmablast diﬀerentiation appeared normal as
indicated by CD38 expression (and CD138, data not shown), there was
reduced upregulation of CD27 in some R635X cases. Although pro-
liferation and plasmablast formation seemed largely normal, there was
no production of class-switched IgG and IgA, the latter expected since
there was a complete absence of surface IgA-expressing B cells (Fig. 2B).
There was IgM production in all cases (Fig. 2C), albeit very low in case
B:II-1, showing the functional inability to produce class-switched im-
munoglobulins ex vivo.
Since Kuehn et al. found a combined B- and T-cell defect in 2 of their
NFKB2 R635X cases based on the clinical phenotype [12], the T cells in
our genetically aﬀected cases were examined in detail. We observed in
both the CD4+ and CD8+ T cells a highly diﬀerentiated T-cell pheno-
type irrespective their clinical status or age (Fig. 2D). By challenging
the T cells with soluble anti-CD3/anti-CD28, an impaired response of
mainly CD8 T cells and B cells was observed in the index patient of
Family A (Fig. 2E), which may have been caused by the lack of pro-
liferation in the large more terminally diﬀerentiated CD28-negative T-
cell population. Although proliferation of CD4+ T cells was seemingly
normal in case A:I-2, the induction of CD4+CXCR5+ T cells upon sti-
mulation was less compared to healthy controls (Supplemental Fig. 1A,
B), which might explain the poor indirect B-cell proliferation upon T-
cell activation. This could indicate that the low number of class-swit-
ched B cells is (at least partially) caused by a concomitant T follicular
helper cell defect. When T-cell receptor (TCR) stimulation was applied
by immobilized anti-CD3 or alternative stimulation with anti-CD2 [17],
the poor proliferative response could be rescued in both CD4 and CD8 T
cells (Supplemental Fig. 1B and data not shown, respectively). In con-
trast to patients with C-terminal mutations in NFKB2 [9,18], pro-
liferation of NK cells was normal upon IL-15 stimulation (data not
shown). Overall, we observed a highly diﬀerentiated T-cell memory
compartment with intact proliferative capacity, which is compatible
with the lack of an in vivo T-cell defect.
Prior reports on the C-terminal NF-κB2 mutations described the
characteristic clinical phenotype of immunodeﬁciency, (mild) ecto-
dermal dysplasia and central adrenal insuﬃciency. The R635X variants
in the ARD of the protein as described by Kuehn et al. [12], were de-
monstrated to behave as GOF mutation. The interrupted p100 was
shown to be less eﬀective in exerting its inhibitory function on both the
non-canonical as the canonical NF-κB signaling pathway. Both path-
ways (activating TLR9 for the canonical and CD40 for non-canonical
signaling) were studied in our functional B-cell experiments. Although a
GOF mutation, we did not observe a hyperactive B-cell response and
only found a reduction in immunoglobulin production coinciding with
CD27dim plasmablasts instead of the usual CD27++ plasmablasts.
Clinical manifestations of T-cell-dependent infection (i.e. warts, un-
common/severe viral or fungal infections), autoimmunity or autoin-
ﬂammation were absent, as opposed to the R635X symptomatic cases
described previously [12]. Mouse models have shown that defective
p52/p100 signaling leads to immunodeﬁciency without clear T-cell
pathology [19,20]. Although patients described with homozygous
mutations in RELB show both B- and T-cell defects [21], the degree of T-
cell dysfunction in NFKB2 deﬁciency remains unclear and seems at least
variable in its clinical penetrance. Instead of the T-cell lymphocytosis in
the 2 previously reported symptomatic cases with R635X GOF muta-
tions [12], we observed mild T-cell lymphopenia in 2 out of the 3 ge-
netically aﬀected subjects in Family A (one being clinically unaﬀected).
Although CID was not present in our families, we conﬁrm the absence
of endocrine and ectodermal manifestations.
In conclusion, NFKB2 mutations in ARD can present as a classic
‘infection-only’ CVID. Being environmental, epigenetic or otherwise,
the clinical and cellular phenotype in NFKB2 deﬁciency has - for as yet
unknown reasons - a highly variable penetrance and expressivity.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.clim.2019.03.010.
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Fig. 2. NFKB2 R635X cases produce no class-switched immunoglobulins ex vivo with a variable T-cell phenotype. (A) Representative ﬂow cytometry plots of CFSE-
labeled PBMCs normalized for B cell numbers after 6 days of culture stimulated with CpG/IL-2 (T cell-independent signaling) and anti-IgM/anti-CD40/IL-21 (T cell-
dependent signaling) gated on CD19+CD20dim/+ B cells. Production of (B) IgG and (C) IgM in the supernatant of before mentioned culture. HD: healthy donor, open
dots are day controls within this study, NFKB1+/−: clinically aﬀected pathologic heterozygous NFKB1 cases published previously by our group [13], NFKB2+/−:
NFKB2 R635X cases within this study. (D) Flow cytometry plots of CD27/CD45RA memory distribution of CD4+ T cells (upper panel) and CD8+ T cells (lower panel).
(E) Histograms of case A:I-2 and A:II-4 alongside a healthy adult control of CFSE-labeled PBMCs normalized for T-cell or B-cell numbers after 6 days of culture
stimulated with soluble anti-CD3/anti-CD28 and gated on CD4+ (left) and CD8+ (middle) T cells, or B cells (right). Blue line represents unstimulated samples, Red
line represents anti-CD3/anti-CD28 stimulated samples. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version
of this article.)
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